143 related articles for article (PubMed ID: 26345555)
1. [Approach to special issues associated with myeloproliferative neoplasms].
Kameda T; Shide K; Kubuki Y
Rinsho Ketsueki; 2015 Aug; 56(8):972-80. PubMed ID: 26345555
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.).
Kreher S; Ochsenreither S; Trappe RU; Pabinger I; Bergmann F; Petrides PE; Koschmieder S; Matzdorff A; Tiede A; Griesshammer M; Riess H; ; ;
Ann Hematol; 2014 Dec; 93(12):1953-63. PubMed ID: 25307456
[TBL] [Abstract][Full Text] [Related]
3. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
4. How I Manage Thrombotic/Thromboembolic Complications in Myeloproliferative Neoplasms.
Koschmieder S
Hamostaseologie; 2020 Feb; 40(1):47-53. PubMed ID: 32050290
[TBL] [Abstract][Full Text] [Related]
5. Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study.
Martinelli I; De Stefano V; Carobbio A; Randi ML; Santarossa C; Rambaldi A; Finazzi MC; Cervantes F; Arellano-Rodrigo E; Rupoli S; Canafoglia L; Tieghi A; Facchini L; Betti S; Vannucchi AM; Pieri L; Cacciola R; Cacciola E; Cortelezzi A; Iurlo A; Pogliani EM; Elli EM; Spadea A; Barbui T
Am J Hematol; 2014 Nov; 89(11):E200-5. PubMed ID: 25042466
[TBL] [Abstract][Full Text] [Related]
6. [Thrombosis and platelet dysfunction in myeloproliferative neoplasms].
Mornet C; Galinat H; Mingant F; Ianotto JC; Lippert E
Rev Med Interne; 2020 May; 41(5):319-324. PubMed ID: 32008800
[TBL] [Abstract][Full Text] [Related]
7. Management of venous thromboembolism in myeloproliferative neoplasms.
Barbui T; De Stefano V
Curr Opin Hematol; 2017 Mar; 24(2):108-114. PubMed ID: 27875375
[TBL] [Abstract][Full Text] [Related]
8. Myeloproliferative disease in pregnancy and other management issues.
Barbui T; Finazzi G
Hematology Am Soc Hematol Educ Program; 2006; ():246-52. PubMed ID: 17124068
[TBL] [Abstract][Full Text] [Related]
9. How to manage thrombosis in myeloproliferative neoplasms.
Barbui T
Curr Opin Oncol; 2011 Nov; 23(6):654-8. PubMed ID: 21986846
[TBL] [Abstract][Full Text] [Related]
10. [Thrombotic risk in myeloproliferative neoplasms: what the general practitioner needs to know].
Casini A; Boehlen F; Lecompte T; de Moerloose P
Rev Med Suisse; 2013 Feb; 9(372):315-8, 320. PubMed ID: 23469399
[TBL] [Abstract][Full Text] [Related]
11. A spotlight on the management of complications associated with myeloproliferative neoplasms: a clinician's perspective.
Greenfield G; McMullin MF
Expert Rev Hematol; 2018 Jan; 11(1):25-35. PubMed ID: 29183180
[TBL] [Abstract][Full Text] [Related]
12. Management of pregnant women with myeloproliferative neoplasms.
Lavi N; Brenner B; Avivi I
Thromb Res; 2013 Jan; 131 Suppl 1():S11-3. PubMed ID: 23452731
[TBL] [Abstract][Full Text] [Related]
13. Bleeding and thrombosis in chronic myeloproliferative disorders: relation of platelet disorders to clinical aspects of the disease.
Wehmeier A; Scharf RE; Fricke S; Schneider W
Haemostasis; 1989; 19(5):251-9. PubMed ID: 2777137
[TBL] [Abstract][Full Text] [Related]
14. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.
Wehmeier A; Südhoff T; Meierkord F
Semin Thromb Hemost; 1997; 23(4):391-402. PubMed ID: 9263357
[TBL] [Abstract][Full Text] [Related]
15. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
16. Thrombosis in myeloproliferative and myelodysplastic syndromes.
Landolfi R; Di Gennaro L
Hematology; 2012 Apr; 17 Suppl 1():S174-6. PubMed ID: 22507813
[TBL] [Abstract][Full Text] [Related]
17. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients.
Pardanani A; Lasho TL; Hussein K; Schwager SM; Finke CM; Pruthi RK; Tefferi A
Mayo Clin Proc; 2008 Apr; 83(4):457-9. PubMed ID: 18380991
[TBL] [Abstract][Full Text] [Related]
18. From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.
Stein BL; Martin K
Blood; 2019 Nov; 134(22):1902-1911. PubMed ID: 31778549
[TBL] [Abstract][Full Text] [Related]
19. Mean platelet volume and risk of thrombotic and bleeding complications in patients with Philadelphia chromosome negative myeloproliferative neoplasms.
Krashin E; Cohen O; Pereg D; Lishner M; Leader A
Blood Coagul Fibrinolysis; 2018 Apr; 29(3):288-293. PubMed ID: 29474204
[TBL] [Abstract][Full Text] [Related]
20. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F.
Tefferi A; Elliott M
Semin Thromb Hemost; 2007 Jun; 33(4):313-20. PubMed ID: 17525888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
